#NuevoSocioAseBio | “AseBio es el lugar perfecto para conectar con posibles colaboradores”

AseBio. What does your company's work bring to the table and what is its strength?

Yolima Puentes. At Duponte, we are dedicated to pharmacogenetics and personalized medicine. We understand that patients' responses to treatments greatly depend on their genetic background. Therefore, we aim to identify genetic variants and other biomarkers that influence drug response and disease predisposition.

Our multidisciplinary business approach encompasses all stages of the diagnostic process, from next-generation sequencing (NGS) of patients to the NGS data analysis using our bioinformatic tool Matchgénica. This tool can predict both disease predisposition and drug response. Additionally, we are developing a new business line focused on pharmacogenomic medical devices.

Our goal is to provide healthcare professionals, researchers, and those working in clinical trials with the best tools to ensure that each patient receives a tailored treatment, thanks to precision medicine. Our strength lies in pharmacogenomic studies and research in patients with various diseases, allowing us to offer a safer and more cost-efficient clinical approach, enabling the implementation of a personalized medicine model focused on patient health.

AseBio. What is AseBio for you?

Yolima Puentes. AseBio is the biggest national association of biotechnology companies, comprising both expert companies in the sector and innovative startups that are set to revolutionize the way we understand science. 

For Duponte, AseBio is the perfect place to connect with potential collaborators, both financial and scientific, who can help us conduct high-quality research, with a direct impact on patients' quality of life and facilitating the integration of personalized medicine into healthcare systems.

AseBio. When did you first hear about AseBio?

Yolima Puentes. In my case, I got to know AseBio during a stay in Seville while working on my doctoral thesis. Later, we had our first in-person meeting at the European forum Transfiere 2024 in Málaga.

AseBio. What do you expect from being part of an association like AseBio?

Yolima Puentes. At Duponte, we believe that being part of AseBio is a great opportunity that will facilitate collaboration on scientific and technological projects, especially in the field of pharmacogenomics. This will enable us to conduct more extensive research, ensuring that the results have a direct positive impact on society.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Yolima Puentes. Yolima Puentes. We are a rapidly growing startup, although our presence in the biotechnology market is still limited. We believe that joining AseBio will help us expand our presence in this sector, allowing us to connect with potential clients who could benefit from our expertise.